Cargando…

Preclinical Evaluation of the Novel, Orally Bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Spontaneous Canine Cancer: Results of a Phase I Study

BACKGROUND: The purpose of this study was to evaluate the activity of Selective Inhibitors of Nuclear Export (SINE) compounds that inhibit the function of the nuclear export protein Exportin 1 (XPO1/CRM1) against canine tumor cell lines and perform a Phase I clinical trial of KPT-335 in dogs with sp...

Descripción completa

Detalles Bibliográficos
Autores principales:	London, Cheryl A., Bernabe, Luis Feo, Barnard, Sandra, Kisseberth, William C., Borgatti, Antonella, Henson, Mike, Wilson, Heather, Jensen, Kiersten, Ito, Daisuke, Modiano, Jaime F., Bear, Misty D., Pennell, Michael L., Saint-Martin, Jean-Richard, McCauley, Dilara, Kauffman, Michael, Shacham, Sharon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913620/ https://www.ncbi.nlm.nih.gov/pubmed/24503695 http://dx.doi.org/10.1371/journal.pone.0087585

Ejemplares similares

Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines
por: Breit, Megan N, et al.
Publicado: (2014)

Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma
por: Sadowski, Abbey R., et al.
Publicado: (2018)

Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185
por: Tabe, Yoko, et al.
Publicado: (2015)

XPO1/CRM1-Selective Inhibitors of Nuclear Export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa)
por: Gravina, Giovanni Luca, et al.
Publicado: (2014)

KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models
por: Gravina, Giovanni Luca, et al.
Publicado: (2015)

Erratum to: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models
por: Gravina, Giovanni Luca, et al.
Publicado: (2016)

Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancer
por: Mendonca, Janet, et al.
Publicado: (2014)

The SINE Compound KPT-350 Blocks Dystrophic Pathologies in DMD Zebrafish and Mice
por: Hightower, Rylie M., et al.
Publicado: (2020)

Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines
por: Fossey, Stacey L, et al.
Publicado: (2011)

Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma
por: Garg, Manoj, et al.
Publicado: (2016)

A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds
por: Crochiere, Marsha L., et al.
Publicado: (2015)

Next-Generation SINE Compound KPT−8602 Ameliorates Dystrophic Pathology in Zebrafish and Mouse Models of DMD
por: English, Katherine G., et al.
Publicado: (2022)

KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells
por: Etchin, J, et al.
Publicado: (2017)

KPT-330 has antitumour activity against non-small cell lung cancer
por: Sun, H, et al.
Publicado: (2014)

Selective nuclear export inhibitor KPT‑330 enhances the radiosensitivity of esophageal carcinoma cells
por: Xu, Jing, et al.
Publicado: (2023)

Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose
por: Bernabe, Luis Feo, et al.
Publicado: (2013)

Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone
por: Muqbil, Irfana, et al.
Publicado: (2016)

Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells
por: Uddin, Md. Hafiz, et al.
Publicado: (2021)

Selective inhibitors of nuclear export (SINE) in hematological malignancies
por: Das, Arundhati, et al.
Publicado: (2015)

Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin
por: Garg, Manoj, et al.
Publicado: (2017)

KPT330 improves Cas9 precision genome- and base-editing by selectively regulating mRNA nuclear export
por: Cui, Yan-ru, et al.
Publicado: (2022)

MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines
por: Fenger, Joelle M., et al.
Publicado: (2016)

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death
por: Kashyap, Trinayan, et al.
Publicado: (2016)

Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells
por: Etchin, J, et al.
Publicado: (2013)

Characterization of STAT3 expression, signaling and inhibition in feline oral squamous cell carcinoma
por: Brown, Megan E., et al.
Publicado: (2015)

Selective inhibitors of nuclear export avert progression in preclinical models of inflammatory demyelination
por: Haines, Jeffery D., et al.
Publicado: (2015)

Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines
por: Couto, Jason I, et al.
Publicado: (2012)

Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents
por: Parikh, Kaushal, et al.
Publicado: (2014)

Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds
por: Crochiere, Marsha, et al.
Publicado: (2015)

Overexpression of miR-9 in mast cells is associated with invasive behavior and spontaneous metastasis
por: Fenger, Joelle M, et al.
Publicado: (2014)

Specific Inhibition of the Nuclear Exporter Exportin-1 Attenuates Kidney Cancer Growth
por: Wettersten, Hiromi I., et al.
Publicado: (2014)

Nucleo-cytoplasmic transport as a therapeutic target of cancer
por: Gravina, Giovanni Luca, et al.
Publicado: (2014)

Give me a SINE: how Selective Inhibitors of Nuclear Export modulate autophagy and aging
por: Kumar, A.V., et al.
Publicado: (2018)

Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor
por: Subhash, Vinod Vijay, et al.
Publicado: (2018)

Characterization of STAT3 activation and expression in canine and human osteosarcoma
por: Fossey, Stacey L, et al.
Publicado: (2009)

SINE (selective inhibitor of nuclear export) – translational science in a new class of anti-cancer agents
por: Gerecitano, John
Publicado: (2014)

Genome-wide mapping of infection-induced SINE RNAs reveals a role in selective mRNA export
por: Karijolich, John, et al.
Publicado: (2017)

The selective inhibitor of nuclear export (SINE) verdinexor exhibits biologic activity against canine osteosarcoma cell lines
por: Breitbach, Justin T., et al.
Publicado: (2021)

Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer
por: Gao, Jiankun, et al.
Publicado: (2014)

Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study
por: Tremblay, Gabriel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_39fvnjjed7d808k99klanou8pu